secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALVELLA THERAPEUTICS, INC. (PVLA)
CIK:        0001583648
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0000950170-25-108422
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palvella Q2 net loss $9.5M; Phase 3 LM trial enrollment exceeded target by 25%
------------------------------------------------------------------------------

- Phase 3 SELVA enrolled 51 subjects (target 40); top-line results expected Q1 2026.
- Cash $70.4M; expected to fund operations into second half of 2027.
- Net loss $9.5M ($0.86/share) vs $4.4M ($2.47); R&D and G&A up due to trial costs.
- Company plans to announce third QTORIN rapamycin indication and second platform candidate before year-end 2025.
- Appointed Ashley Kline as Chief Commercial Officer; added to Russell 2000/3000 indexes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583648/000095017025108422/0000950170-25-108422-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583648/000095017025108422/pvla-20250814.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-108422

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer